![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GILEAD SEEKS TO END ROCHE PACT
GILEAD SEEKS TO END ROCHE PACT
June 27, 2005
Gilead plans to split from its flu pill partner Roche for its "lack of commitment," the company said Thursday. The Foster City, Calif., company said it wants to cut loose from its Swiss partner for breaching a 1996 agreement for the development and licensing of Tamiflu, an antiviral pill used to treat and prevent influenza. Gilead said it has sent Roche a notice of termination. Elsewhere, developing countries are stocking up on the antiviral drug, and last month, Roche quadrupled its production capacity, in case a human flu pandemic caused by evolving strains of the avian flu plaguing Asia should break out.
The Street (http://www.thestreet.com/stocks/biotech/10229456.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct